Navigation Links
Deputy HHS Secretary, Investors and Entrepreneurs to Share Their Vision of Upcoming New Era in Health Care
Date:9/18/2013

WASHINGTON, Sept. 18, 2013 /PRNewswire-USNewswire/ -- One of the hottest trends in the pharmaceutical and biotechnology industries in recent years has been the development of orphan products or treatments for people with rare diseases. 

(Logo: http://photos.prnewswire.com/prnh/20110719/DC37656LOGO-b)

Now, industry-watchers are wondering how legislation such as the Affordable Care Act and the FDA Safety and Innovation Act of 2012 as well as current global market and investment trends may affect this rapidly growing field.

That topic will take center stage with an all-star platform of speakers Oct. 7-9 at the U.S. Conference on Rare Diseases and Orphan Products in Bethesda, MD.  Speakers will include Deputy HHS Secretary William Corr; entrepreneur David Scheer; and investors David Mott of New Enterprise Associates; Kris Jenner, Rock Springs Capital; Rajiv Kaul, Fidelity Investments; and Jean-Francois Formela, MD, Atlas Venture.

The conference will also provide an opportunity for approximately 100 representatives of rare disease patient organizations to share first-hand their needs and concerns.  In addition, senior Food and Drug Administration officials will lead sessions on FDA's new patient-focused initiative, accelerated regulatory pathways, and other current topics.

"We'll be focusing on the new era in health care," said Peter L. Saltonstall, president and CEO of the National Organization for Rare Disorders (NORD), a nonprofit organization representing the 30 million Americans with rare diseases. 

"There have been tremendous recent advances in research, regulatory practices, level of industry/investor interest, and related legislation.  We want to pull it all together and address the key question:  What does this mean to patients and to those seeking to develop innovative new therapies? And what can we learn from each other to ensure that greater progress is made in the future?"

The conference is being sponsored by NORD and DIA (the Drug Information Association), in collaboration with FDA, NIH (the National Institutes of Health), and EURORDIS (Rare Diseases Europe).  It will take place at the Marriott North Hotel and Conference Center in Bethesda.  It is open to all, and online registration is available.

In addition to sessions on the investment environment, globalization, and research frontiers, other topics and speakers will include:

  • William Shrank, MD, of Harvard Medical School and former head of research at the Centers for Medicare and Medicaid Services Innovation Center on "The Health Care System of the Future"
  • Janet Woodcock, MD, Director of FDA's Center for Drug Evaluation and Research, on FDA Initiatives on Orphan Products
  • A panel chaired by Pamela Gavin of NORD on "Assuring Patient Access to Treatments"
  • A panel chaired by Kevin Lee, PhD, of Pfizer on "How Industry and Patients Can Partner in Rare Disease" and
  • A panel of representatives of health care payers on "How Payers Make Decisions Related to Orphan Products" and
  • A panel chaired by John C. McKew, PhD, of the National Institutes of Health on "FDA and NIH Perspectives on Drug Repurposing"


'/>"/>
SOURCE National Organization for Rare Disorders (NORD)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Former Clinton Deputy Solicitor General sheds light on flaws in Federal Trade Commissions case in FTC v. Actavis Inc.
2. Deborah Autor, FDAs Deputy Commissioner for Global Regulatory Operations and Policy, to Join Mylan
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
5. InspireMD to Present at Harvard Investors Group on June 27 in New York
6. Life Sciences Companies Webcast Live to Online Investors, July 12th, at RetailInvestorConferences.com
7. First Warning Systems Receives Investment by Members of the Reno Angels and Local Investors
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In American Oriental Bioengineering Inc. To Contact The Firm Regarding The August 22, 2012 Lead Plaintiff Deadline
9. Varian Medical Systems to Proceed with Year End Review and Webcast for Investors at ASTRO Meeting in Boston
10. Life Sciences Entrepreneurs S.L.U. Announces the First Financing of the Antiplatelet Candidate NmC by Spanish and Swiss Investors
11. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MAP Pharmaceuticals, Inc. - MAPP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... WASHINGTON , May 9, 2017  Demonstrating ... the board of directors for the Pharmaceutical Research ... criteria for membership. Biopharmaceutical companies will now have ... in order to be eligible to join PhRMA. ... criteria, the board is sending a clear message ...
(Date:5/6/2017)... , May 5, 2017   Provista , a ... more than 200,000 customers, today announced Jim Cunniff ... wealth of executive and business experience to Provista, including most ... pharmacy in California . He assumed his ... "Jim is a great fit for Provista," says Jody ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... ... Policy Solutions is vehemently opposed to Donald Trump’s budget, “A New Foundation for ... that inspires fear, demonizes the poor, marginalizes underserved populations, undermines productivity, and destroys ...
(Date:5/24/2017)... Orion, Michigan (PRWEB) , ... ... ... a disease affecting the female reproductive tract in which the endometrial lining ... pelvic structures causing inflammation and pain. Patients experiencing painful intercourse, painful periods, ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... If you are thinking of a visit ... interested in business architecture, October is the perfect time to visit. , Business Architecture Associates ... à la carte offering for individuals, as a 4-½ day package for individuals, and as ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... and nonprofit hospitals and health systems in the nation and help their organizations ... led professional organizations and been instrumental in developing successful hospital and health system ...
(Date:5/24/2017)... Shoreview, MN (PRWEB) , ... May 24, 2017 ... ... manufacturer of polyvinylidene fluoride (PVDF) based sleep diagnostics sensors, announced today it had ... network now consists of a mix of domestic and rest of world (ROW) ...
Breaking Medicine News(10 mins):